Johns Hopkins University will deliver distinguished figures from the US and South Korea’s life-science communities collectively in Songdo on Thursday for a high-level assembly geared toward accelerating the industrialization of cutting-edge biotechnology and deepening transpacific collaboration.
The JHU Global Biotechnology Innovation Summit, held in the Incheon Free Economic Zone in Songdo, gathers representatives from main universities, state analysis institutes, global drugmakers and enterprise traders.
The invite-only assembly will perform as a strategic discussion board for aligning rising applied sciences with business pathways and for constructing a extra structured mannequin of Korea-US cooperation in biopharma, organizers mentioned.
Faculty from Johns Hopkins, Harvard University and the University of Cambridge will be part of heads of Korean nationwide analysis institutes and senior executives from firms.
Participating firms embrace Samsung Biologics Co., Celltrion Inc., DreamCIS Inc. and Curi Bio Co.
The occasion is co-organized by Johns Hopkins alongside the Incheon Free Economic Zone Authority (IFEZ), Korea Institute of Industrial Technology (KITECH), Korea Basic Science Institute (KBSI), Yonsei University, Incheon National University, Pohang University of Science and Technology (POSTECH), the National Cancer Center, Korea Business Incubation Association (KoBIA) and Okay-BioLabHub.
ORGANOIDS, MICROPHYSIOLOGICAL SYSTEMS
Discussions will middle on applied sciences considered as pivotal to the subsequent section of global biomanufacturing.
These embrace organoids and microphysiological methods (MPS) – lab-grown, human-tissue-mimicking platforms which might be gaining traction as options to animal testing – in addition to AI-enabled drug discovery, precision drugs, translational analysis, superior biomanufacturing and cross-border industry-academia collaboration fashions.
Executives from Samsung Biologics and different Korean firms are anticipated to define new organoid-based contract analysis group (CRO) providers, highlighting how miniature, stem-cell-derived organ fashions can speed up preclinical work.
With the US FDA more and more recognizing non-animal testing modalities, demand for organoid-based platforms is projected to develop quickly, giving Korean CROs and contract drug manufacturing organizations (CDMOs) an opportunity to carve out an early market place.
The summit will probably be held at Gyeongwonjae by Walkerhill in Songdo.
PRACTICAL COLLABORATION PLATFORM
Celltrion will current its open-innovation analysis technique, detailing how the biosimilar drugmaker goals to broaden discovery pipelines by means of partnerships with global universities, startups and specialist labs.
IFEZ Commissioner Yun Won-sok mentioned the summit marks “a pivotal moment for Songdo’s emergence as a global biotechnology innovation hub.”
He mentioned the authority would help an ecosystem for biotechnology R&D, industrialization and worldwide enlargement.
Deok-Ho Kim, professor of Johns Hopkins and JHU’s Global Biotech Innovation Center (JHBIC) director, mentioned the assembly is designed as “a practical collaboration platform that goes beyond academic exchange.”
He mentioned he hopes Songdo will anchor a brand new mannequin of bilateral biotech innovation between Korea and the US.
Established in 2003 as South Korea’s first and largest free financial zone, IFEZ has been Korea’s main business hub west of Seoul.
Upon taking workplace final yr, Commissioner Yun has taken steps to improve the Incheon Free Economic Zone’s appeal as a destination for foreign capital.